D’Erasmo L, Di Costanzo A, Gallo A, Bruckert E, Arca M. ApoCIII: a multifaceted protein in cardiometabolic disease. Metabolism. 2020;113: 154395.

Article  Google Scholar 

Lai CQ, Parnell LD, Ordovas JM, Karathanasis SK. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol. 2005;16(2):153–66.

Article  CAS  Google Scholar 

Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol. 2003;83(1):47–68.

Article  CAS  Google Scholar 

Rodríguez M, Rehues P, Iranzo V, Mora J, Balsells C, Guardiola M, et al. Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects. J Proteomics. 2022;251: 104398.

Article  Google Scholar 

Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:239–45.

Article  CAS  Google Scholar 

Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 2014;1841:919–33.

Article  CAS  Google Scholar 

Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine HN. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol. 2017;11(1):224-233.e2.

Article  Google Scholar 

Gordts PLS, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855–66.

Article  Google Scholar 

Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42(10):1578–85.

Article  CAS  Google Scholar 

Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479–90.

Article  CAS  Google Scholar 

Yamazaki A, Ohkawa R, Yamagata Y, Horiuchi Y, Lai SJ, Kameda T, et al. Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL). Biol Chem. 2021;402(4):439–49.

Article  CAS  Google Scholar 

Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122(1):105–15.

Article  CAS  Google Scholar 

Taskinen MR, Boren J. Why Is Apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease? Curr Atheroscler Rep. 2016;18:59.

Article  Google Scholar 

Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31:140–6.

Article  CAS  Google Scholar 

van Capelleveen JC, Lee SR, Verbeek R, Kastelein JJP, Wareham NJ, Stroes ESG, et al. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: the EPIC-Norfolk prospective population study. J Clin Lipidol. 2018;12(6):1493–501.

Article  Google Scholar 

Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–5.

Article  CAS  Google Scholar 

Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.

Article  Google Scholar 

HDL Working Group of the Exome Sequencing Project NHL Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.

Genetics GT. APOC3 mutations lower CVD risk. Nat Rev Cardiol. 2014;11(9):496.

Article  Google Scholar 

Crawford DC, Dumitrescu L, Goodloe R, Brown-Gentry K, Boston J, McClellan B Jr, et al. Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the epidemiologic architecture for genes linked to environment (EAGLE) study. Circ Cardiovasc Genet. 2014;7(6):848–53.

Article  Google Scholar 

Reyes-Soffer G, Sztalryd C, Horenstein RB, Holleran S, Matveyenko A, Thomas T, et al. Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2019;39(1):63–72.

Article  CAS  Google Scholar 

Natarajan P, Kohli P, Baber U, Nguyen KDH, Sartori S, Reilly DF, et al. Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: the multi-ethnic bioimage study. J Am Coll Cardiol. 2015;66:2053–5.

Article  CAS  Google Scholar 

The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1): 22–31.

Wulff AB, Nordestgaard BG, Tybjærg-Hansen A. APOC3 Loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol. 2018;38:660–8.

Article  CAS  Google Scholar 

Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab. 2014;20(3):387–9.

Article  CAS  Google Scholar 

Silbernagel G, Scharnagl H, Kleber ME, Hoffmann MM, Delgado G, Stojakovic T, et al. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Atherosclerosis. 2020;311:84–90.

Article  CAS  Google Scholar 

Goyal S, Tanigawa Y, Zhang W, Chai JF, Almeida M, Sim X, et al. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. Lipids Health Dis. 2021;20(1):113.

Article  CAS  Google Scholar 

Zhang JZ, Xie X, Ma YT, Zheng YY, Yang YN, Li XM, et al. Association between apolipoprotein C-III gene polymorphisms and coronary heart disease: a meta-analysis. Aging Dis. 2016;7(1):36–44.

Article  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

Article  Google Scholar 

Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri MA. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta. 2019;490:1–5.

Article  CAS  Google Scholar 

Aguilar Salinas CA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Rev Curr Opin Lipidol. 2020;31(3):132–9.

Article  Google Scholar 

Nakajima K, Nakano T, Tokita Y, Nagamine T, Inazu A, Kobayashi J, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta. 2011;412:1306–18.

Article  CAS  Google Scholar 

Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24:95–109.

Article  CAS  Google Scholar 

Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020;26(6):964–73.

Article  CAS  Google Scholar 

Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489–503.

Article  CAS  Google Scholar 

• Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791–4806. This consensus critically assesses current understanding of the structure, function, and metabolism of TRLs and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD).

Nordestgaard BG. New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–63.

Article  CAS  Google Scholar 

Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2007;193(2):321–7.

Article  CAS  Google Scholar 

Christ A, Günther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell. 2018;172(1–2):162-175.e14.

Article  CAS  Google Scholar 

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;317:2200–6.

Article  Google Scholar 

Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26:56–63.

Article  CAS  Google Scholar 

Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010;121:1722–34.

Article  CAS  Google Scholar 

Pavlic M, Valéro R, Duez H, Xiao C, Szeto L, Patterson BW, et al. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660–5.

Article  CAS  Google Scholar 

Guan Y, Hou X, Tian P, Ren L, Tang Y, Song A, et al. Elevated levels of apolipoprotein CIII increase the risk of postprandial hypertriglyceridemia. Front Endocrinol. 2021;12: 646185.

Article  Google Scholar 

•• Katzmann JL, Werner CM, Stojakovic T, März W, Scharnagl H, Laufs U. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 2020;19:116. This study emphasizes the hypothesis that lowering apoC-III reduces residual cardiovascular risk.

Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb. 2009;16:6–11.

Article  CAS  Google Scholar 

Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-functio